Tuttiquotidiani is completely free. Every day we aggregate news from 100+ sources and generate original AI summaries for you. Help us keep the service running with a small donation, or become TQ Pro for just €1/month.

Donate now TQ Pro - 1€/mo

AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?

Posted on July 11, 2026
By CNBC
4 Views
1 min read

AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?

For years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results.